Stay updated on Optimal Pembrolizumab and Chemotherapy Sequence in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Optimal Pembrolizumab and Chemotherapy Sequence in NSCLC Clinical Trial page.

Latest updates to the Optimal Pembrolizumab and Chemotherapy Sequence in NSCLC Clinical Trial page
- Check2 days agoChange DetectedThe site's footer revision identifier changed from v3.8.0 to v3.8.1, with no apparent change to the study details.SummaryDifference0.0%

- Check9 days agoChange DetectedThe study record for a completed Phase 2 trial comparing the sequencing of pembrolizumab and platinum-based chemotherapy in stage IV non-small-cell lung cancer is displayed, with study details, results, and supporting documents.SummaryDifference75%

- Check16 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0. The study page still displays a 403 Forbidden error instead of the record.SummaryDifference0.2%

- Check30 days agoChange DetectedA general NIH transition notice was added to the page, and the site revision label changed from v3.7.1 to v3.7.2.SummaryDifference1%

- Check44 days agoChange DetectedThe ClinicalTrials.gov footer now shows revision v3.7.1 instead of v3.7.0. The page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check58 days agoChange Detected- The page now displays a 403 Forbidden error, with a minimal header and a Home link, replacing the previous study record content. This means the study details on this page are no longer accessible.SummaryDifference21%

Stay in the know with updates to Optimal Pembrolizumab and Chemotherapy Sequence in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Optimal Pembrolizumab and Chemotherapy Sequence in NSCLC Clinical Trial page.